Last week, the Wall Street Journal published an opinion piece highlighting the recent amendments to the Federal Rule of Civil Procedures (FRCP). The amendments focus on mass tort litigation and were effective as of December 1, 2025. They aim to standardize the early stages of multidistrict litigations (MDLs) and encourage early vetting of cases. We have previously blogged about the history and purpose of MDLs. While they were originally established to increase efficiency in adjudicating cases of common facts, the litigation has become voluminous and more challenging to resolve.  

As stated in the article, “MDLs now represent 68% of the federal civil docket, up from 29% in 2012.” The opinion piece provides background on the growth of mass tort litigation, describes the difficulty courts face in managing large MDLs, and explains why the amendments are critical. One concern raised (substantiating the increase in case volume) is the “ability of trial lawyers to gather huge plaintiff groups without first having to establish a factual basis for the individual claims.” The article references the MDL involving Merck & Co.’s painkiller Vioxx, stating that “almost a third of injury claims were unsubstantiated.” 

Another example that has been widely discussed is the Taxotere litigation. The drug has been the subject of two separate MDLs, both of which drew significant attention due to large inventories amid disputed scientific and factual foundations. As highlighted in a recent KCIC analysis of the five largest MDLs, modern mass tort litigation involves mountains of raw data that must be managed before it can be meaningfully understood. Historically, defendants have sought relief using case management tools or data analytics systems such as KCIC’s Ligado Platform. In Taxotere, the court issued a Lone Pine order requiring plaintiffs to substantiate injury and causation, which revealed that 80% of plaintiffs could not produce evidence of injury.  

The contrast between these solutions and the amendments to the FRCP is that the reform prompts action at an early stage of the proceedings. This is not a drastic change in the management of MDLs, but rather a shift in the order of when certain concerns can be raised and triaged. Sometimes a small adjustment can make a critical difference—and could ultimately save all those involved in MDLs time, burden, and cost. We will continue to monitor developments in MDLs and hope to see positive results and greater efficiency from this change.